Schizophrenia Research Forum - A Catalyst for Creative Thinking


Seeman P. Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al. J Clin Psychopharmacol. 2012 Apr ; 32(2):291-2; author reply 292-293. Pubmed Abstract